RECEPTOR - 386 Annonces

Friday 15 August 2025

Quantité : 5mg*10vial - Prix : USD 80

Tirzepatide shares a similar sequence to semaglutide, with the lys side chain of the sequence bearing a PEG modification, which is a functional group of the peptide, as well as the ability to increase the water solubility of the sequence.The primary physiological function of TirzepaChemicalbookti...

Thursday 14 August 2025

Quantité : 60mg*10via - Prix : USD 650

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 60mg*10via - Prix : USD 650

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 50mg*10via - Prix : USD 550

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 40mg*10via - Prix : USD 450

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 30mg*10via - Prix : USD 360

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 20mg*10via - Prix : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Wednesday 13 August 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 12 August 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 12 August 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 12 August 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 12 August 2025

Quantité : 1kg; 25kg;

Palmitoylethanolamide (PEA) is a fatty acid amide produced in the body that binds to and activates the peroxisome proliferator-activated receptor alpha (PPAR-α). It was initially described as an agonist to the type 2 cannabinoid receptor (CB2), though it is now recognized that PEA...

Saturday 09 August 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Saturday 09 August 2025

Quantité : 10mg*10via - Prix : USD 180

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Saturday 09 August 2025

Quantité : 1kg; 25kg;

Minoxidil is a type of oral drug that is clinically used to lower blood pressure, and it is also called Loniten and piperidine diamine. Minoxidil is an antihypertensive drug that is clinically used to treat intractable, primary or renal hypertension. It can also be used to treat severe...

Friday 08 August 2025

Quantité : 1kg; 25kg;

Levodopa is an amino acid precursor of dopamine with antiparkinsonian properties. Levodopa is a prodrug that is converted to dopamine by DOPA decarboxylase and can cross the blood-brain barrier. When in the brain, levodopa is decarboxylated to dopamine and stimulates the dopaminergic receptors...

Wednesday 06 August 2025

CJC-1295 is an incredibly effective growth hormone and works by causing another substance to be secreted. It stimulates the release of your own body's growth hormone which. CJC-1295 is able to increase growth hormone naturally by binding to receptors for growth hormone releasing hormone...

Wednesday 06 August 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 05 August 2025

Quantité : 30mg*10via - Prix : USD 360

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Tuesday 05 August 2025

Quantité : 5mg*10vial - Prix : USD 130

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 01 August 2025

Quantité : 1kg; 25kg;

O-methyl-2-(2-aminoethyl)-pyrrolidine, also known as 1-methyl-2-aminoethylpyrrolidine, is a widely used pharmaceutical intermediate. After the hydrogen on the nitrogen is replaced, it can be made into a series of new drugs. Most of these drugs are 5-HT receptors and can treat insomnia...

Friday 01 August 2025

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Friday 01 August 2025

PT-141 was approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. It activates melanocortin receptors. PT-141 is used for the treatment of erectile dysfunction in men and for the treatment of hypoactive ual desire disorder in women...

Thursday 31 July 2025

Quantité : 1kg; 25kg;

Lacosamide is a novel NMDA receptor glycine site binding antagonist, belonging to a new class of functional amino acids, and an anticonvulsant drug with a new dual mechanism of action. It can selectively promote the slow inactivation of sodium channels and regulate collapse response...

Thursday 31 July 2025

Quantité : 1kg; 25kg;

Clemastine fumarate is a potent, long-acting, fast-acting, highly selective histamine H1 receptor antagonist that simultaneously blocks H1 receptors and antagonizes cytotoxicity. It is mainly used clinically for allergic diseases such as allergic skin diseases and allergic rhinitis...

Thursday 31 July 2025

Quantité : 1kg; 25kg;

Maropitant citrate hydrate is a synthetic compound that has emerged as a significant medication in veterinary medicine, particularly for its antiemetic properties. The discovery of maropitant can be traced back to the early 2000s, when researchers aimed to develop new agents that...

Thursday 31 July 2025

Quantité : 20mg*10via - Prix : USD 300

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...

Thursday 31 July 2025

Quantité : 15mg*10via - Prix : USD 230

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It is an important tool for obesity research. It is an antidiabetic agent against type 2 diabetes (T2D)...